What's new
Cystic Fibrosis Forum (EXP)

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

A "cure"? Please explain...

J

juls

Guest
A

Ditto to what everyone is saying. We just got back from the CFRI conference and Dr. Milla gave a great talk about all of these and how/who they will work for etc.

He said that in the future many treatments will be mutation specific so it will be very important to know your mutations.
 
J

juls

Guest
A

Ditto to what everyone is saying. We just got back from the CFRI conference and Dr. Milla gave a great talk about all of these and how/who they will work for etc.

He said that in the future many treatments will be mutation specific so it will be very important to know your mutations.
 
J

juls

Guest
A

Ditto to what everyone is saying. We just got back from the CFRI conference and Dr. Milla gave a great talk about all of these and how/who they will work for etc.

He said that in the future many treatments will be mutation specific so it will be very important to know your mutations.
 
J

juls

Guest
A

Ditto to what everyone is saying. We just got back from the CFRI conference and Dr. Milla gave a great talk about all of these and how/who they will work for etc.

He said that in the future many treatments will be mutation specific so it will be very important to know your mutations.
 
J

juls

Guest
A

Ditto to what everyone is saying. We just got back from the CFRI conference and Dr. Milla gave a great talk about all of these and how/who they will work for etc.
<br />
<br />He said that in the future many treatments will be mutation specific so it will be very important to know your mutations.
 

Spartan936

New member
A

Personally, I think in another 10-15 years most symptoms of CF will be almost entirely treatable, and the average life span will be in the fifties. The science right now is looking better than it ever has. But whether I'll live to benefit from it... is another question entirely. Bwhahahahaha!
 

Spartan936

New member
A

Personally, I think in another 10-15 years most symptoms of CF will be almost entirely treatable, and the average life span will be in the fifties. The science right now is looking better than it ever has. But whether I'll live to benefit from it... is another question entirely. Bwhahahahaha!
 

Spartan936

New member
A

Personally, I think in another 10-15 years most symptoms of CF will be almost entirely treatable, and the average life span will be in the fifties. The science right now is looking better than it ever has. But whether I'll live to benefit from it... is another question entirely. Bwhahahahaha!
 

Spartan936

New member
A

Personally, I think in another 10-15 years most symptoms of CF will be almost entirely treatable, and the average life span will be in the fifties. The science right now is looking better than it ever has. But whether I'll live to benefit from it... is another question entirely. Bwhahahahaha!
 

Spartan936

New member
A

Personally, I think in another 10-15 years most symptoms of CF will be almost entirely treatable, and the average life span will be in the fifties. The science right now is looking better than it ever has. But whether I'll live to benefit from it... is another question entirely. Bwhahahahaha!
 

Transplantmommy

New member
A

<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>kitomd21</b></i>

Here's one that mentions being mutation-specific (also from CFF website)...



VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.



The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</end quote></div>

That's the one that I was thinking of! Thank you!!! Now my next question is.....are any of these studies going to be able to benefit people who have already had Tx? I will have to ask my docs about this next week when I go!
 

Transplantmommy

New member
A

<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>kitomd21</b></i>

Here's one that mentions being mutation-specific (also from CFF website)...



VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.



The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</end quote></div>

That's the one that I was thinking of! Thank you!!! Now my next question is.....are any of these studies going to be able to benefit people who have already had Tx? I will have to ask my docs about this next week when I go!
 

Transplantmommy

New member
A

<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>kitomd21</b></i>

Here's one that mentions being mutation-specific (also from CFF website)...



VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.



The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</end quote></div>

That's the one that I was thinking of! Thank you!!! Now my next question is.....are any of these studies going to be able to benefit people who have already had Tx? I will have to ask my docs about this next week when I go!
 

Transplantmommy

New member
A

<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>kitomd21</b></i>

Here's one that mentions being mutation-specific (also from CFF website)...



VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.



The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</end quote>

That's the one that I was thinking of! Thank you!!! Now my next question is.....are any of these studies going to be able to benefit people who have already had Tx? I will have to ask my docs about this next week when I go!
 

Transplantmommy

New member
A

<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>kitomd21</b></i>
<br />
<br />Here's one that mentions being mutation-specific (also from CFF website)...
<br />
<br />
<br />
<br />VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.
<br />
<br />
<br />
<br />The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</end quote>
<br />
<br />That's the one that I was thinking of! Thank you!!! Now my next question is.....are any of these studies going to be able to benefit people who have already had Tx? I will have to ask my docs about this next week when I go!
<br />
<br />
 
Top